The Lead MSD-001 program series
MSD-001 is currently in human studies to demonstrate that profoundly therapeutic emotional and cognitive states can be precision-designed.
Unlocking safe and reliable access to a wider range of emotional and cognitive states
Mindstate Design Labs is a clinical-stage AI neuroengineering platform and drug development company addressing the mental health crisis by creating a new way that we can change our minds.
Reduced motion is active, so this page shows the content sequence without scroll-linked morphing.
Mindstate Design Labs overview
Mindstate Design Labs is a clinical-stage AI neuroengineering platform and drug development company mapping molecules, neural systems, and subjective states to develop mental health therapeutics.
Osmanthus platform
The Osmanthus platform combines machine learning and statistical models to map biochemical targets to psychoactive effects, including emotional, perceptual, and cognitive states.
MSD-001 pipeline and fixed-dose combinations
MSD-001 is the lead asset in a pipeline of fixed-dose combinations designed to reliably induce specific psychoactive profiles for psychiatric conditions with high unmet need.
Careers at Mindstate Design Labs
Mindstate Design Labs careers are open to exceptional talent. Candidates can submit an application, and the team will reach out when an opportunity aligns with their skills.
Osmanthus
Our AI-powered platform maps the biological basis of emotion, perception, and cognition. Synthesizing 60,000 human reports of psychoactive drug effects with biochemical data, Osmanthus identifies how specific neurotransmitter receptor combinations produce distinct emotional and cognitive states.
Lead Asset: MSD-001
MSD-001 is a pharmaceutical compound that can temporarily enable significant emotional & cognitive flexibility. We're developing multiple combinations with the base ingredient of MSD-001. Each combination is built to reliably induce a state like empathy, awe, or enhanced aesthetic perception - offering new therapeutic possibilities to transform our deepest psychological afflictions.
Our Pipeline
Discovery
Target Validation
Lead Identification
Lead Optimization
IND-Enabling Studies
Phase 1
MSD-001
MSD-001: Lead asset through IND-enabling studies.
MSD-101
MSD-101: Program through lead optimization.
MSD-201
MSD-201: Program through lead optimization.
MSD-X01
MSD-X01: Early discovery program.
MSD-X02
MSD-X02: Earliest discovery program.
MSD-XXX
MSD-XXX: Future program series.
The MSD-X02 program series
MSD-X02 series is designed to act on a novel central nervous system target to produce select psychoactive effects.
MSD-XXX
Future programs based on high-throughput Osmanthus screening optimize for single-molecule, multi-target action producing a broader range of psychoactive effects.
Our Team
Team
Dillan DiNardoCo-Founder & CEO
Thomas Ray, PhDScientific Co-Founder
Rob Silva, PhDChief Scientific Officer
Tilmann Brotz, PhDHead of Preclinical Development
Ken Colley, MD, PhDMedical Director
Jianhong Wang, PhDHead of DMPK
Jessica Smith Beaver, PhD, MLSHead of Regulatory Affairs
Tom Richardson, PhDHead of Medicinal Chemistry
Jasminder SotoHead of Clinical Operations
Antonio SocorroHead of Drug Product & Formulation
Tegan JohnsonSenior Director of Operations
Michael HoyosHead of Business Development
Josie KinsPhenomenologist & AI Performance Specialist
Bethany Leins, PMPProject Manager, Drug Development
Drew Thieme, PhDCheminformatician
Ahnjili ZhuParris, PhDData Scientist
Advisors
Frederick Barrett, PhDScientific Advisor
Danilo Bzdok, MD, PhDScientific Advisor
Robin Carhart-Harris, PhDScientific Advisor
David Erritzoe, MD, PhDScientific Advisor
Andrew HesselBusiness Development Advisor
Rand Hindi, PhDScientific Advisor
Andrew Newberg, MDScientific Advisor
Peter Wipf, PhDScientific Advisor
News
Follow our journey as we repurpose the mechanisms of psychedelics to pioneer a new paradigm in mental health therapeutics.
WIREDA Startup Used AI to Make a Psychedelic Without the Trip
TimeSafer Psychedelic Drugs May Be Coming
The Washington PostFDA Gives an Early Nod to Psychedelic Research
The AtlanticTripping on Nothing
Fierce BiotechAfter crunching 70k 'trip reports', Mindstate looks to test first AI-derived psychedelic on humans
Popular MechanicsScience Has a Powerful New Tool to Unlock the Mysteries of Consciousness—And Even Help You Reach Transcendence
Lucid NewsMindstate Uses AI to Design “Next-Gen” Psychedelics Combined With 5-MeO-MiPT
TechCrunchOur favorite startups from YC’s Summer 21 Demo Day, Part 2
Business InsiderHere are the 7 hottest psychedelics startups that are set to take off in 2022, according to 3 top VCs in the spaceBusiness InsiderA Y Combinator startup that's creating a new class of psychedelics just raised $11.5 million from big Silicon Valley investors
EntrepreneurThe Burgeoning Psychedelics Industry Is Full of Money and Good Intentions. But Can It Avoid All Of Cannabis's Mistakes?
CrunchbasePsychedelics Provide New Frontier For Venture Funding, But Nuances Prevail
MIT Technology ReviewWhat do psychedelic drugs do to our brains? AI could help us find out
ViceThe Future of Psychedelic Medicine Will Be Drugs You’ve Never Heard Of
BloombergAre Hallucinogen Look-Alikes Illegal? DEA Delay Creates Limbo
The Wall Street JournalInvestors See Far Out Profits in Psychedelic Medicine
Big ThinkThe next era of psychedelics may be precision-designed states of consciousness
BenzingaY Combinator Startup Uses AI To Design New Drug-Induced States Of Consciousness
Fast CompanyVC money keeps flowing into psychedelics-based mental health
AxiosPsychedelic startup Mindstate's $11.5M trip
GENTransforming Psychedelics into Approved Medicines
FuturismStartups Are Biohacking Psychedelic Drugs to Make Sure You Never Have a Bad Trip Again
Inspired to make an impact?
We're always on the lookout for exceptional talent. Submit an application below, and we'll reach out when an opportunity aligns with your skills and aspirations.
Apply Now